Nonagen Bioscience

Executive Summary

Nonagen Bioscience is a private, physician-led diagnostics company headquartered in San Diego, focused on developing advanced immunoassay-based tests for oncology. Its lead product, Oncuria®, is a multiplex protein immunoassay designed for the detection and monitoring of bladder cancer, aiming to provide a non-invasive alternative to cystoscopy. The test leverages a panel of protein biomarkers to improve diagnostic accuracy and enable earlier intervention. Founded in 2016, Nonagen operates in the high-need area of bladder cancer, where current surveillance methods are invasive, costly, and have limited sensitivity. The company's approach seeks to address these gaps by offering a simple urine-based test that could enhance patient compliance and reduce healthcare burdens. While Nonagen has not disclosed specific clinical or regulatory milestones, the diagnostics market for bladder cancer is sizable and growing, with significant demand for non-invasive tools. Oncuria's multi-analyte platform could differentiate it from single-biomarker tests, potentially improving specificity and sensitivity. The company's success hinges on generating robust clinical validation data and navigating FDA clearance pathways. As a private entity with limited public information, Nonagen carries higher risk but also substantial upside if Oncuria achieves regulatory approval and commercial adoption. Key upcoming catalysts include clinical study readouts, regulatory submissions, and potential strategic partnerships to accelerate commercialization.

Upcoming Catalysts (preview)

• TBDPivotal clinical validation study data readout for Oncuria70% success
• TBDFDA 510(k) submission or breakthrough device designation60% success
• TBDStrategic partnership or licensing deal with a urology-focused diagnostics company50% success